全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Stability Indicating HPLC Determination of Risperidone in Bulk Drug and Pharmaceutical Formulations

DOI: 10.1155/2011/124917

Full-Text   Cite this paper   Add to My Lib

Abstract:

The objective of the current study was to develop a validated stability-indicating assay method (SIAM) for risperidone after subjecting it to forced decomposition under hydrolysis, oxidation, photolysis, and thermal stress conditions. The liquid chromatographic separation was achieved isocratically on a symmetry C18 column (5?μm size, 250?mm × 4.6?mm i.d.) using a mobile phase containing methanol: acetonitrile (80?:?20, v/v) at a flow rate of 1?mL/min and UV detection at 280?nm. Retention time of risperidone was found to be . The method was linear over the concentration range of 10–60?μg/mL with a limit of detection and quantitation of 1.79 and 5.44?μg/mL, respectively. The method has the requisite accuracy, specificity, sensitivity, and precision to assay risperidone in bulk form and pharmaceutical dosage forms. Degradation products resulting from the stress studies did not interfere with the detection of Risperidone, and the assay is thus stability indicating. 1. Introduction Risperidone, 4-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl] ethyl]-3-methyl-2,6-diazabicyclo[4.4.0]deca-1,3-dien-5-one an atypical antipsychotic drug used for the treatment of schizophrenia, the mixed and manic states associated with bipolar disorder, and irritability in children with autism [1]. Blockade of dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia such as hallucinations, delusions, and erratic behavior and speech. Blockade of serotonergic 5-HT2 receptors in the mesocortical tract causes an excess of dopamine, resulting in an increase in dopamine transmission and an elimination of core negative symptoms. It has high affinity for D2 dopaminergic receptors. It has actions at several 5-HT (serotonin) receptor subtypes. These are , linked to weight gain, , linked to its antipsychotic action and relief of some of the extrapyramidal side effects experienced with the typical neuroleptics through action at . Like other 5-HT2 antagonists, risperidone also binds at alpha (1)-adrenergic receptors and, to a lesser extent, at histamine H1 and alpha (2)-adrenergic receptors [2]. Several analytical methods have been reported in the literature for the analysis of Risperidone from pharmaceutical dosage form. The techniques include chemiluminescence [3], RP HPLC [4], TLC [5], and visible spectrophotometry [6] and so forth forms. There are numerous methods to quantify Risperidone in biological fluid and human plasma, including HPLC combined with capillary electrophoresis [7], HPLC-DAD [8], HPLC-MS/ MS [9], RP-HPLC [10], LC-MS/MS [11–13],

References

[1]  http://en.wikipedia.org/wiki/Risperidone.
[2]  http://www.drugbank.ca/drugs/DB00734.
[3]  Z. Song and C. Wang, “Sensitive chemiluminescence assay for risperidone in pharmaceutical preparations,” Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 3, pp. 491–494, 2004.
[4]  S. Bladania, K. K. Bhatt, R. S. Mehta, and D. A. Shah, “RP-HPLC estimation of risperidone in tablet dosage forms,” Indian Journal of Pharmaceutical Sciences, vol. 70, no. 4, pp. 494–497, 2008.
[5]  S. K. Patel and N. J. Patel, “TLC determination of amitriptyline HCl, trifluoperazine HCl, risperidone and alprazolam in pharmaceutical products,” Chromatographia, vol. 69, no. 3-4, pp. 393–396, 2009.
[6]  A. Goyal and I. Singhvi, “Visible spectrophotometric determination of aceclofenac in tablet formulation,” Asian Journal of Chemistry, vol. 18, no. 4, pp. 3157–3159, 2006.
[7]  Danel, C. Barthélémy, D. Azarzar et al., “Study of coplexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity electrophoresis and (1)H NMR spectroscopy,” Journal of Chromatography A, vol. 1215, no. 1-2, pp. 185–193, 2008.
[8]  M. A. Raggi, F. Bugamelli, C. Sabbioni, M. A. Saracino, and C. Petio, “HPLC-DAD determination of plasma levels of the antipsychotic risperidone and its main metabolite for toxicological purposes,” Journal of Separation Science, vol. 28, no. 3, pp. 245–250, 2005.
[9]  M. Huang, J. Shentu, J. Chen, J. Liu, and H. Zhou, “Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers,” Journal of Zhejiang University Science, vol. 9, no. 2, pp. 114–120, 2008.
[10]  S. M. Foroutan, A. Zarghi, A. Shafaati, and A. Khoddam, “Rapid high performance liquid chromatographic determination of risperidone in human plasma,” Indian Journal of Pharmaceutical Research, vol. 5, no. 1, p. 37, 2006.
[11]  B. ?abovska, S. L. Cox, and A. A. Vinks, “Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS,” Journal of Chromatography B, vol. 852, no. 1-2, pp. 497–504, 2007.
[12]  R. S. Tomar, T. J. Joseph, A. S. R. Murthy, D. V. Yadav, G. Subbaiah, and K. V. S. R. Krishna Reddy, “Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms,” Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 1, pp. 231–235, 2004.
[13]  M. D. Meulder, B. M. Remmerie, R. de Vries et al., “Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine,” Journal of Chromatography B, vol. 870, no. 1, pp. 8–16, 2008.
[14]  C. Danel, N. Azaroual, A. Brunel et al., “Study of the complexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity capillary electrophoresis and 1H NMR spectroscopy,” Journal of Chromatography A, vol. 1215, no. 1-2, pp. 185–193, 2008.
[15]  International Federation of Pharmaceutical Manufactures & Associations (IFPMA), “Stability testing of new drug substances and products (Q1AR2),” in Proceedings of the International Conference on Harmonization (ICH '03), International Federation of Pharmaceutical Manufactures & Associations (IFPMA), Brussels, Belgium, 2003.
[16]  International Federation of Pharmaceutical Manufactures & Associations (IFPMA), “Validation of analytical procedure,” in Proceedings of the International Conference on Harmonization (ICH '96), Methodology Q2(R1), International Federation of Pharmaceutical Manufactures & Associations (IFPMA), Geneva, Switzerland, 1996.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133